Guidelines for Drugs of Abuse Testing vers 2012 - Brenneisen

Foreword
These revised SCDAT Guidelines were originally published by the Work Group on Drugs of Abuse
Testing (AGSA). The SCDAT, successor to AGSA, is a work group composed of members of the
following institutions:
• Swiss Association of Pharmacists (pharmaSuisse)
• Swiss Society of Clinical Chemistry (SGKC)
• Swiss Society of Legal Medicine (SGRM)
• Swiss Association of the Diagnostic Equipment and Product Industry (SVDI)
• University of Bern.
These guidelines are intended as recommendations. They are not legally binding in nature.
Harmonization in drug analyses is the objective.
The use of drug analysis for the various questions in the therapeutic and forensic sectors as well
as in specific workplaces can have far-reaching consequences of a professional and social nature
for those affected. For this reason, the greatest possible care must be taken when conducting
analyses and interpreting the results. These guidelines support analytical laboratories in their
adherence to requisite quality assurance measures.
The guidelines are periodically revised and enlarged.
In addition, the SCDAT provides consultation both to the laboratories that conduct drug testing and
the Swiss Quality Control Centers (inter-laboratory test centers).
______________________________________________________________________________________
Although SCDAT takes the utmost care in assuring the correctness of the information in printed or electronic form, it
does not assume liability with regard to the correctness, accuracy, timeliness, reliability, and comprehensiveness of this
information as contained herein. SCDAT expressly reserves the right to alter, delete, or temporarily refrain from
publishing the contents, in full or in part, at any time without prior notice thereof. Any liability claims against SCDAT for
damages of a material or immaterial nature ensuing from the access to, the use or non-use of the published information,
the inappropriate use of the link, or from technical defects, are hereby excluded.
Page 6 of 63